Pharmaceutical News

RSS

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.

2 Jul 2010

Studies demonstrate analgesic properties of synthetic cannabinoid

A new compound similar to the active component of marijuana (cannabis) might provide effective pain relief without the mental and physical side effects of cannabis, according to a study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jul 2010

Columbia Laboratories shareholders approve Watson's aquisition terms

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that shareholders of Columbia Laboratories, Inc. (Nasdaq: CBRX) have approved the terms and conditions of the previously announced acquisition by Watson of the U.S. rights to Columbia's CRINONE® and PROCHIEVE® progesterone gel product line and 11,200,000 shares of Columbia common stock.

2 Jul 2010

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Columbia Laboratories, Inc. announced that in a special meeting of stockholders held this morning, stockholders approved the sale of substantially all of Columbia's progesterone related assets to Watson Pharmaceuticals, Inc.. Stockholders also voted to increase the number of authorized shares of Columbia's common stock, $0.01 par value per share, from 100,000,000 to 150,000,000.

2 Jul 2010

ORS, zinc supplements and rotavirus vaccine can reduce diarrheal disease

Researchers from the Johns Hopkins Bloomberg School of Public Health urge wider use of oral rehydration solution (ORS), zinc supplementation and rotavirus vaccine to reduce the deaths from diarrheal disease worldwide.

2 Jul 2010

Anti-aging supplement: A fountain of hope for would-be mothers

According to the American Pregnancy Association, six million women a year deal with infertility. Now, a Tel Aviv University study is giving new hope to women who want to conceive ― in the form of a pill they can find on their drugstore shelves right now.

2 Jul 2010

Teva launches antidepressant Venlafaxine HCl ER Capsules

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. The brand product had annual sales of approximately $2.75 billion in the United States, based on IMS sales data.

2 Jul 2010

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Sun Pharma announced launch of generic Exelon, rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

2 Jul 2010

Draft Guidance on judicious use of antimicrobials in food-producing animals

The U.S. Food and Drug Administration today issued draft guidance intended to help reduce the development of resistance to medically important antimicrobial drugs used in food-producing animals.

2 Jul 2010

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.

2 Jul 2010

AP reports on how newly approved meningitis vaccine could 'revolutionalize' prevention of disease in Africa

The WHO's recent prequalification approval of a low-cost meningitis vaccine could "help prevent epidemics in Africa for the first time, revolutionizing how doctors fight outbreaks of the deadly disease," the Associated Press reports.

2 Jul 2010

Roche, X-Chem sign collaborative agreement

X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.

2 Jul 2010

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Caraco Pharmaceutical Laboratories, Ltd. has started shipping rivastigmine tartrate capsules. These products, approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA), are therapeutically equivalent to Exelon® capsules from Novartis.

2 Jul 2010

GSK, Genmab amend ofatumumab agreement

GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.

2 Jul 2010

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

Furiex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No. 7,718,705 includes claims directed to dosing dapoxetine on an as-needed basis, capturing the advantage dapoxetine has over other compounds in the same class, which require a pre-loading period for efficacy.

2 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Older adults taking the antibiotic combination trimethoprim-sulfamethoxazole (TMP-SMX)—widely prescribed for urinary tract infections—are at increased risk of elevated potassium levels, called hyperkalemia, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

2 Jul 2010

Lupin's Famotidine for Oral Suspension receives FDA approval

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.

2 Jul 2010

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Wound Management Technologies, Inc. announced an important milestone in its planned growth strategy. Its wholly owned subsidiary Wound Care Innovations signed a distribution agreement with KOMED, LLC of Georgia for direct response advertising on television and niche online marketing of CellerateRx® in the United States.

1 Jul 2010

Pharmaceutical News

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Studies demonstrate analgesic properties of synthetic cannabinoid

Columbia Laboratories shareholders approve Watson's aquisition terms

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

ORS, zinc supplements and rotavirus vaccine can reduce diarrheal disease

Anti-aging supplement: A fountain of hope for would-be mothers

Teva launches antidepressant Venlafaxine HCl ER Capsules

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Draft Guidance on judicious use of antimicrobials in food-producing animals

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

AP reports on how newly approved meningitis vaccine could 'revolutionalize' prevention of disease in Africa

Roche, X-Chem sign collaborative agreement

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

GSK, Genmab amend ofatumumab agreement

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Lupin's Famotidine for Oral Suspension receives FDA approval

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News